Fifth Third Bancorp
AKCA

Fifth Third Bancorp’s Akcea Therapeutics Inc AKCA Stock Holding History

Fifth Third Bancorp’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-150
Closed -$4K – 2377
2018
Q2 		$4K Buy
+150
New +$3.58K ﹤0.01% 2112

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fifth Third Bancorp's AKCA Position: Q3 2018 in Review

Fifth Third Bancorp sold out of Akcea Therapeutics Inc (AKCA) in Q3 2018, closing a stake of 150 shares — an estimated $4K sold.

Fifth Third Bancorp first reported a position in AKCA in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 65 funds tracked by Wall St. Rank hold AKCA as of Q3 2018.

  • Fifth Third Bancorp reported no remaining Akcea Therapeutics Inc position as of Q3 2018 after selling out during the quarter.
  • Fifth Third Bancorp sold 150 Akcea Therapeutics Inc shares in Q3 2018, an estimated $4K.
  • Fifth Third Bancorp first reported a position in Akcea Therapeutics Inc in Q2 2018 and held it in 1 quarter.
  • Fifth Third Bancorp's Akcea Therapeutics Inc position peaked at $4K in Q2 2018.
  • 65 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2018.

Based on Fifth Third Bancorp's 13F filing for Q3 2018, filed 14 Nov 2018.